Century Therapeutics has secured $135.0 million in new investment capital from investors, the company announced today. This funding round marks a significant milestone for the biotechnology firm, which is dedicated to developing advanced cell therapies for cancer.
The company specializes in creating genetically-engineered, universal iPSCs-derived immune effector cell products. These include Natural Killer (NK) cells, T cells, Dendritic cells, and macrophages, all designed to specifically target a range of hematologic and solid tumor cancers. Century Therapeutics' core mission revolves around developing off-the-shelf cell therapies, which aim to expand patient access and significantly advance the course of cancer care by providing readily available treatment options.
This substantial capital infusion is intended to fuel the continued advancement of Century Therapeutics' innovative pipeline. The company plans to utilize the funds to accelerate its preclinical and clinical development programs, further expand its research and development efforts, and enhance its manufacturing capabilities to support future product launches. The investment reflects confidence in the company's platform and its potential to deliver transformative treatments.
The newly raised capital is expected to play a critical role in Century Therapeutics' strategic initiatives, enabling it to push its therapeutic candidates through various development stages more rapidly. By focusing on its commitment to universal, accessible cell therapies, the company aims to solidify its position in the oncology landscape. This funding positions Century Therapeutics to continue its work in expanding patient access to cutting-edge cancer treatments and fulfilling its vision for the future of cancer care.
.png&w=3840&q=75)
